IL114151A - Insulin analog formulations - Google Patents

Insulin analog formulations

Info

Publication number
IL114151A
IL114151A IL11415195A IL11415195A IL114151A IL 114151 A IL114151 A IL 114151A IL 11415195 A IL11415195 A IL 11415195A IL 11415195 A IL11415195 A IL 11415195A IL 114151 A IL114151 A IL 114151A
Authority
IL
Israel
Prior art keywords
insulin analog
analog formulations
formulations
insulin
analog
Prior art date
Application number
IL11415195A
Other languages
English (en)
Other versions
IL114151A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114151A0 publication Critical patent/IL114151A0/xx
Publication of IL114151A publication Critical patent/IL114151A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11415195A 1994-06-16 1995-06-14 Insulin analog formulations IL114151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
IL114151A0 IL114151A0 (en) 1995-10-31
IL114151A true IL114151A (en) 2000-09-28

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11415195A IL114151A (en) 1994-06-16 1995-06-14 Insulin analog formulations

Country Status (38)

Country Link
US (1) US5474978A (sr)
JP (2) JP3171541B2 (sr)
KR (1) KR100382326B1 (sr)
CN (1) CN1105576C (sr)
AT (1) AT408720B (sr)
BE (1) BE1009408A5 (sr)
BR (1) BR9502795A (sr)
CA (1) CA2151560C (sr)
CH (2) CH689250A5 (sr)
CO (1) CO4410203A1 (sr)
CZ (1) CZ287484B6 (sr)
DE (1) DE19521720B4 (sr)
DK (1) DK173015B1 (sr)
ES (1) ES2091727B1 (sr)
FI (1) FI118207B (sr)
FR (2) FR2721214B1 (sr)
GB (1) GB2291427B (sr)
GR (1) GR1003004B (sr)
HU (1) HU227240B1 (sr)
IE (1) IE68853B1 (sr)
IL (1) IL114151A (sr)
IT (1) IT1276723B1 (sr)
LU (1) LU88626A1 (sr)
MY (1) MY115631A (sr)
NL (1) NL1000566C2 (sr)
NO (1) NO322128B1 (sr)
NZ (1) NZ272359A (sr)
PE (1) PE19496A1 (sr)
PL (1) PL181310B1 (sr)
PT (1) PT101722B (sr)
RO (1) RO113530B1 (sr)
RS (1) RS49577B (sr)
RU (1) RU2152399C2 (sr)
SE (1) SE509052C2 (sr)
SI (1) SI9500200A (sr)
TW (1) TW421596B (sr)
UA (1) UA26874C2 (sr)
ZA (1) ZA954943B (sr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US6274549B1 (en) * 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes
RU2204411C2 (ru) * 1996-06-20 2003-05-20 Ново Нордиск А/С Инсулиновые препараты, содержащие углеводы
IL127366A0 (en) * 1996-06-20 1999-10-28 Novo Nordisk As Insulin preparations containing NaCl
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
EP1121144B1 (en) * 1998-10-16 2002-06-05 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
JP2002527488A (ja) * 1998-10-16 2002-08-27 ノボ ノルディスク アクティーゼルスカブ メントールを含有する肺送達のためのインスリン製剤
EP1131089B1 (en) * 1998-11-18 2004-02-18 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DK1383540T3 (da) * 2000-07-31 2009-08-24 Univ Bar Ilan Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
RU2202365C2 (ru) * 2001-07-20 2003-04-20 Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН Способ приготовления быстродействующего раствора инсулина для инъекций
CA2471144C (en) 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
EP1633876B1 (en) 2003-06-17 2008-08-20 SemBioSys Genetics Inc. Methods for the production of insulin in plants
AU2004261319B2 (en) * 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
JP4903690B2 (ja) 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体
JP4995080B2 (ja) * 2004-05-14 2012-08-08 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するためのアリールケトン化合物および組成物
WO2005115341A2 (en) * 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
CA2573856A1 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
CN102772788B (zh) * 2004-10-05 2017-06-06 诺和诺德公司 包含结晶的胰岛素和溶解的胰岛素的药物制剂
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
US8367606B2 (en) 2005-08-29 2013-02-05 Healor Ltd. Method and compositions for prevention and treatment of diabetic and aged skin
KR20080049128A (ko) 2005-09-19 2008-06-03 에미스페어 테크놀로지스, 인코포레이티드 Ｎ-(5-클로로살리실로일)-8-아미노카프릴산 이나트륨염의결정형
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009527526A (ja) * 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
US8466199B2 (en) * 2007-03-21 2013-06-18 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents
EP2514412A1 (en) * 2007-04-30 2012-10-24 Novo Nordisk A/S Highly Concentrated Insulin Solutions and Compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
RU2555557C2 (ru) 2008-07-31 2015-07-10 Кейз Вестерн Ризев Юнивесити Инсулин, стабилизированный галогеном
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
DK3228320T3 (da) 2008-10-17 2020-03-09 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
CN102316892B (zh) 2009-02-12 2014-06-04 西马生物医学计划公司 心肌营养素-1用于治疗代谢病的用途
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
PL3417871T3 (pl) 2009-11-13 2021-06-14 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
EP2538945A4 (en) * 2010-02-24 2013-07-24 Emisphere Tech Inc Oral b12 therapy
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9309209B2 (en) 2010-09-30 2016-04-12 Solvay Sa Derivative of epichlorohydrin of natural origin
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
CN105749253A (zh) 2011-03-01 2016-07-13 Jds治疗有限公司 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9908925B2 (en) 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
WO2014015078A1 (en) 2012-07-17 2014-01-23 Michael Weiss O-linked carbohydrate-modified insulin analogues
KR102367083B1 (ko) 2012-11-13 2022-02-24 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
NZ707160A (en) 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CN104870469A (zh) 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
ES2949095T3 (es) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
KR20190140048A (ko) 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
CA3157995A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
MX2022012208A (es) 2020-03-31 2022-12-15 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales.
US20240374735A1 (en) 2020-11-19 2024-11-14 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US12139502B2 (en) 2022-05-18 2024-11-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
WO1990007522A1 (en) * 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
IL93282A (en) * 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
AU6995794A (en) * 1993-06-21 1995-01-17 Novo Nordisk A/S Aspb28 insulin crystals
DE122004000035I2 (de) * 1993-09-17 2009-08-06 Novo Nordisk As Acyliertes insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
PT101722B (pt) 1997-02-28
BR9502795A (pt) 1996-03-12
BE1009408A5 (fr) 1997-03-04
AU694501B2 (en) 1998-07-23
CA2151560C (en) 2000-05-09
JPH083067A (ja) 1996-01-09
CZ154295A3 (en) 1996-02-14
FI118207B (fi) 2007-08-31
FR2721214B1 (fr) 1997-09-26
MY115631A (en) 2003-08-30
PL181310B1 (pl) 2001-07-31
DE19521720A1 (de) 1995-12-21
FR2741078B1 (fr) 1998-08-07
HUT73186A (en) 1996-06-28
FI952931A0 (fi) 1995-06-14
ES2091727A1 (es) 1996-11-01
GB2291427B (en) 1998-09-16
KR960000924A (ko) 1996-01-25
CO4410203A1 (es) 1997-01-09
TW421596B (en) 2001-02-11
KR100382326B1 (ko) 2003-07-07
CH689935A5 (de) 2000-02-15
JP2001199899A (ja) 2001-07-24
RU95110109A (ru) 1997-05-10
IL114151A0 (en) 1995-10-31
CZ287484B6 (en) 2000-12-13
RU2152399C2 (ru) 2000-07-10
DK67795A (da) 1995-12-17
GR950100229A (en) 1996-02-29
DK173015B1 (da) 1999-11-15
CN1105576C (zh) 2003-04-16
LU88626A1 (fr) 1996-02-01
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
HU9501716D0 (en) 1995-08-28
ITMI951278A1 (it) 1996-12-14
NL1000566A1 (nl) 1995-12-18
YU39695A (sh) 1997-08-22
RS49577B (sr) 2007-04-10
NO952357L (no) 1995-12-18
FR2721214A1 (fr) 1995-12-22
RO113530B1 (ro) 1998-08-28
UA26874C2 (uk) 1999-12-29
AT408720B (de) 2002-02-25
PT101722A (pt) 1995-12-29
ZA954943B (en) 1997-09-14
CH689250A5 (de) 1999-01-15
HU227240B1 (en) 2010-12-28
AU2168095A (en) 1996-01-04
IE68853B1 (en) 1996-07-24
PE19496A1 (es) 1996-06-01
PL309098A1 (en) 1995-12-27
IT1276723B1 (it) 1997-11-03
FR2741078A1 (fr) 1997-05-16
CN1122248A (zh) 1996-05-15
SE9502167L (sv) 1995-12-17
CA2151560A1 (en) 1995-12-17
DE19521720B4 (de) 2009-09-03
HK1015138A1 (en) 1999-10-08
SE9502167D0 (sv) 1995-06-14
GB9512038D0 (en) 1995-08-09
SE509052C2 (sv) 1998-11-30
NO322128B1 (no) 2006-08-21
NZ272359A (en) 1996-10-28
JP3171541B2 (ja) 2001-05-28
NL1000566C2 (nl) 1996-12-03
ATA101695A (de) 2001-07-15
ITMI951278A0 (it) 1995-06-14
IE950436A1 (en) 1995-12-27
NO952357D0 (no) 1995-06-14
FI952931L (fi) 1995-12-17
US5474978A (en) 1995-12-12
SI9500200A (en) 1996-02-29
GR1003004B (el) 1998-11-05

Similar Documents

Publication Publication Date Title
GB2291427B (en) Insulin analog formulations
GB2290294B (en) Monomeric insulin analog formulations
IL117696A0 (en) Monomeric insulin analog formulations
AP9500733A0 (en) Pharmaceutical formulations
IL133348A0 (en) Stable insulin formulations
ZA951781B (en) Pharmaceutical formulations
AU731636C (en) Insulin analog formulations
AU694501C (en) Insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
GB2327424B (en) Monomeric insulin analog formulations
HK1015138B (en) Insulin analog formulations
GB9413542D0 (en) Pharmaceutical formulations
AU2168295A (en) Monomeric insulin analog formulations
AU738101C (en) Monomeric insulin analog formulations
GB9406050D0 (en) Formulations
GB9408419D0 (en) Formulations
GB9409464D0 (en) Formulations
GB9408163D0 (en) Pharmaceutical formulations
GB9408164D0 (en) Pharmaceutical formulations
GB9414216D0 (en) Pharmaceutical formulations
GB9417953D0 (en) Pharmaceutical formulations
GB9426113D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations
GB9408162D0 (en) Pharmaceutical formulations
GB9401738D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired